Literature DB >> 27841060

Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study.

Isabella Martignoni1, Valentina Trotta1, Wing-Hin Lee2, Ching-Yee Loo2, Michele Pozzoli2,3, Paul M Young2, Santo Scalia1, Daniela Traini2.   

Abstract

This study focuses on development and in vitro characterisation of a nasal delivery system based on uncoated or chitosan-coated solid lipid microparticles (SLMs) containing resveratrol, a natural anti-inflammatory molecule, as an effective alternative to the conventional steroidal drugs. The physico-chemical characteristics of the SLMs loaded with resveratrol were evaluated in terms of morphology, size, thermal behaviour and moisture sorption. The SLMs appeared as aggregates larger than 20 μm. In vitro nasal deposition was evaluated using a USP specification Apparatus E 7-stage cascade impactor equipped with a standard or a modified nasal deposition apparatus. More than 95% of resveratrol was recovered onto the nasal deposition chamber and stage 1 of impactor, suggesting that the SLMs mostly deposited in the nasal cavity. Additionally, the SLMs were not toxic on RPMI 2650 nasal cell line up to a concentration of approximately 40 μM of resveratrol.

Entities:  

Keywords:  Nasal drug delivery; chitosan; in vitro models; solid lipid microparticles

Mesh:

Substances:

Year:  2016        PMID: 27841060     DOI: 10.1080/02652048.2016.1260659

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  2 in total

Review 1.  Significance of Resveratrol in Clinical Management of Chronic Diseases.

Authors:  Awais Wahab; Kuo Gao; Caixia Jia; Feilong Zhang; Guihua Tian; Ghulam Murtaza; Jianxin Chen
Journal:  Molecules       Date:  2017-08-18       Impact factor: 4.411

2.  DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment.

Authors:  Zerong Li; Wenmei Qiao; Chenghao Wang; Heqiao Wang; Mengchao Ma; Xinyu Han; Jingling Tang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.